All AbMole products are for research use only, cannot be used for human consumption.
Amuvatinib (formerly known as MP470), is a novel receptor tyrosine kinase inhibitor, it has inhibitory effect on prostate cancer in combination with Erlotinib in vitro and in vivo. Amuvaninib (MP470) inhibited RAD51 protein expression and HR. Amuvatinib also inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3, which are frequently dysregulated in variety of tumors. Amuvatinib (MP470) exhibits low microM IC50 in prostate cancer cell lines. When LNCaP were treated with MP470 in combination with Erlotinib, additive effects on both cytotoxicity and induction of apoptosis were observed. Furthermore, the MP470-Erlotinib combination produced 30-65% dose-dependent tumor growth inhibition (TGI) in a LNCaP mouse xenograft model. Amuvatinib (MP470) sensitized cells to IR and MMC, agents that are selectively toxic to HR-deficient cells. Mutant forms of c-Kit are often associated with tumor chemoresistance.
Sci Rep. 2024 Jun 25;11(1):28.
RUNX1 regulates MCM2/CDC20 to promote COAD progression modified by deubiquitination of USP31
Amuvatinib purchased from AbMole
| Molecular Weight | 447.51 |
| Formula | C23H21N5O3S |
| CAS Number | 850879-09-3 |
| Solubility (25°C) | DMSO 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| ABT-869
ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR. |
| Tivozanib (AV-951)
Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. |
| Axitinib
Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. |
| Regorafenib
Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
| Nintedanib
Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
